Mission of DTMC
To use science as a vehicle for improving the treatment of Substance Use Disorders (SUDs) and their medical consequences, focusing on the identification, evaluation, and development of safe and effective therapeutics, such as medications, biologics. devices, digital, and behavioral interventions.
The DTMC achieves this mission by:
- Supporting and conducting research on innovative pharmacological and non-pharmacological approaches for treating SUDs and facilitating recovery.
- Collaborating with pharmaceutical companies and other federal agencies involved in therapeutic development.
- Facilitating the regulatory approval process for new medications, devices, and digital therapeutics for SUDs.
- Promoting the development of reliable methods to measure the safety and efficacy of SUD treatments in preclinical models and clinical trials.
- Investigating the medical consequences of SUDs, including infections such as HIV and Hepatitis C, and developing treatments for SUDs comorbid with other health conditions.
- Disseminating the knowledge gained from DTMC-supported research to improve the treatment outcomes of patients with SUDs.
DTMC Pipelines of Therapeutics
- Opioid Use Disorder and Overdose
Opioid Use Disorder and Overdose Early Preclinical Late Preclinical Phase I Clinical Trials Phase II Clinical Trials New Formulation - Naltrexone 2-month injection
- BICX104 Naltrexone 3-month implant
- OLANI (Naltrexone 6-month implant)
- DLP-160 (Naltrexone 6-month implant)
- BIOPIN 6 (Naltrexone 6 month implant)
- Novel naltrexone transdermal patch (NNTP)
- LAAM
- LYN-014
- LYN-013
- Nalmefene implant
- Nanoparticle-based ADF
- PF614 - MPAR (Nafamostat/ Oxycodone ADF)
- NaxSwab (Pocket Naloxone Corp)
- Buprenorphine
If you have questions, please contact Ivan Montoya or Marta de Santis
- Stimulant Use Disorder and Overdose
Stimulant Use Disorder and Overdose Early Preclinical Late Preclinical Clinical Trials Phase I Phase Ib Phase II Phase III - SBI-0801315/SBI-0799220
- CocH5-Fc(M6) Cocaine Hydrolase
- SBX-518
- Pioglitazone
- Rotigotine
- Bupropion/Naltrexone
- EMB-001
- TNX-1300
- IXT-m200 (OD)
- IXT-m200 (MUD)
If you have questions, please contact Katrina Foster or Ivan Montoya
- Tobacco Use Disorder
Tobacco Use Disorder Early Preclinical Late Preclinical Clinical Trials Phase I Phase Ib Phase II Phase III If you have questions, please contact Evan Herrmann.
- Cannabis Use Disorder
Cannabis Use Disorder Early Preclinical Late Preclinical Clinical Trials Phase I Phase II Phase III If you have questions, please contact Aidan Hampson.
- Therapeutic Devices Pipeline
If you have questions, please contact Will Aklin or Jennifer Wong
- Behavioral Therapies Pipeline
If you have questions, please contact Will Aklin
- Digital Therapeutics Pipeline
If you have questions, please contact Will Aklin
- Medical Consequences Grants Portfolio
If you have questions, please contact Will Aklin
Research Programs:
- Pharmacotherapies Development Program
- The Addiction Treatment Discovery Program (ATDP)
- Regulatory Affairs Program
- Behavioral Therapy Development Program
- Device Development for Substance Use Disorders
- Digital Therapeutics Development Program
- Clinical Trial Outcomes Development Program
- NIDA Drug Supply Program
Division Listings:
- Office of the DTMC Director (OD)
- Chemistry and Pharmaceutics Branch (CPB)
- Clinical/Medical Branch (CMB)
- Clinical Research Grants Branch (CRGB)
- Medications Discovery and Toxicology Branch (MDTB)
- Regulatory Affairs Branch (RAB)
Funding Opportunities
Staff Listings:
Mailing Address:
Division of Therapeutics & Medical Consequences
National Institute on Drug Abuse
C/O NIH Mail Center
3WFN MSC 6016
16071 Industrial Drive – Dock 11
Gaithersburg, MD 20892*
*(Use 20892 for U.S. Postal Service, 20877 for UPS and FedEx)
(301) 443-6173 (phone)
(301) 443-2599 (fax)